Filing Flows › Health Care › Aspire-Lakewood Holdings (ASBP)
Aspire-Lakewood Holdings (ASBP) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Aspire-Lakewood Holdings (ASBP) Q2 2026 earnings results →
Aspire-Lakewood Holdings made $63K in Q2 2026. Operating margin n/m, net loss $1.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $63K in Q2 2026, up 123% from the previous quarter.
Operating costs exceeded revenue by $2.7M, an operating margin of -4244.1%. The quarter ended with a net loss of $1.3M, narrower than the previous quarter's $3.2M loss. Non-operating items added $1.4M, -111% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.1M. Non-cash charges added back $144K of share-based compensation. Working capital and other items used $1.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $63K | — | n/m | −$1.3M | −$2.1M |
| Q1 2026 | 10-Q | May 15, 2026 | $28K | — | n/m | −$3.2M | −$3.0M |
| Q4 2025 | 10-K | Mar 30, 2026 | $4K | — | n/m | −$4.7M | −$928K |
| Q3 2025 | 10-Q | Nov 14, 2025 | $2K | — | n/m | −$1.9M | −$1.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Aspire-Lakewood Holdings
Aspire is an early-stage biopharmaceutical company. As a Delaware corporation formed in February 2025, the Company engages in the business of developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Business Combination we were a privately held Puerto Rico corporation incorporated in September 2021. Our internet address is www.aspirebiolabs.com. We expect to generate revenue through developing and marketing drugs and nutraceuticals using the technology for the novel sublingual delivery. Further, from time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue.
In its own words, from its 10-K, filed Mar 30, 2026.
Aspire-Lakewood Holdings against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ASBP Aspire-Lakewood Holdings | Q2 2026 | $63K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Aspire-Lakewood Holdings 10-Q on SEC EDGAR · CIK 1847345 · Pharmaceutical Preparations
13F: who owns ASBP and who is buying
More on ASBP
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results